Aaron Gardner focuses his practice on M&A and licensing transactions
Latham & Watkins LLP has welcomed Aaron Gardner to the firm’s New York office as a partner in the corporate department and as a member of the healthcare and life sciences practice group. Gardner focuses his practice on M&A and licensing transactions across the life sciences industry.
“Aaron is a welcome addition to the New York office as well as the healthcare and life sciences practice group,” said Marc Jaffe, office managing partner at Latham & Watkins’ New York office. “His broad transactional experience, diverse skill set and unique perspective will complement our team and be an asset to clients in New York and around the globe.”
Gardner represents pharmaceutical, biotechnology, consumer nutrition and medical device companies and their investors on a wide range of commercial transactions, including licences, collaborations, product divestitures, option transactions, carve-outs, joint ventures, strategic alliances, and mergers and acquisitions. His experience covers the full span of the product life cycle, as well as various therapeutic areas and modalities.
“Aaron has impressive depth and versatility across complex transactional matters, which distinguishes him from others in the field,” said Judith Hasko, vice chair of Latham’s healthcare and life sciences practice. “The synergies between his practice and our cutting-edge life sciences offerings make him a strong fit for our dynamic team. Aaron’s arrival also reinforces our commitment to growing with our life sciences clients, providing them the best possible service and ensuring we stay ahead of industry trends.”
Gardner joins Latham from Arnold & Porter Kaye Scholer LLP in New York.
